Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Terheyden

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Frontiers in Cardiovascular Medicine|June 25, 2024
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicityYing Wang, Carolin Ertl, Christina Schmitt, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
Cancers|April 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in GermanyPeter Mohr, Emilie Scherrer, Chalid Assaf, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2025
Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADORegNoah Zimmermann, Julian Kött, Tim Zell, et al.
Frontiers in Immunology|March 11, 2025
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADORegAndrea Forschner, Katharina C Kähler, Martin Gschnell, et al.
Journal for Immunotherapy of Cancer|January 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanomaNicola Herold, Jonas Bochem, Johanna Leyens, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Frontiers in Cardiovascular Medicine|June 25, 2024
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicityYing Wang, Carolin Ertl, Christina Schmitt, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
Cancers|April 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in GermanyPeter Mohr, Emilie Scherrer, Chalid Assaf, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2025
Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADORegNoah Zimmermann, Julian Kött, Tim Zell, et al.
Frontiers in Immunology|March 11, 2025
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADORegAndrea Forschner, Katharina C Kähler, Martin Gschnell, et al.
Journal for Immunotherapy of Cancer|January 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanomaNicola Herold, Jonas Bochem, Johanna Leyens, et al.
Pageof 13